New Posts New Posts RSS Feed - Metastatic Cancer and  the CCR5 Receptor
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Metastatic Cancer and the CCR5 Receptor

 Post Reply Post Reply
Author
FullTilt View Drop Down
Newbie
Newbie


Joined: Mar 03 2019
Status: Offline
Points: 3
Post Options Post Options   Thanks (0) Thanks(0)   Quote FullTilt Quote  Post ReplyReply Direct Link To This Post Topic: Metastatic Cancer and the CCR5 Receptor
    Posted: Mar 03 2019 at 11:21am
New Phase 1b/2 study just getting underway that could possibly stop the metastasis of TNBC by blocking the CCR5 receptor.




https://www.apnews.com/cbc9f6d1b31beea54e3ac3adb6131e98

Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

BASED ON STRONG RESULTS IN ITS PRE-CLINICAL ANIMAL STUDY, CYTODYN FILES FOR ORPHAN DRUG DESIGNATION FOR TRIPLE-NEGATIVE BREAST CANCER

VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model for cancer through six weeks with leronlimab (PRO 140). Based on these results, CytoDyn announced yesterday its plans for the expansion of pre-clinical animal studies into eight cancer indications, driven in part on prior research by Dr. Pestell suggesting that CCR5 inhibition may disrupt signaling and ultimately the spread of CCR5+ Circulating Tumor Cells (CTC’s).

In Dr. Pestell’s research laboratory, pre-clinical studies were conducted on mice using Pfizer’s HIV drug maraviroc in breast and prostate cancer.  Results were most encouraging using these CCR5 inhibitors, which ultimately led Dr. Pestell to design experiments applying leronlimab (PRO 140) to metastatic mouse models. The results of this pre-clinical study using leronlimab (PRO 140) in mice showed a reduction in breast cancer metastasis of more than 98% over the six-week period of the study.  The mouse xenograft model is designed to mimic human breast cancer metastasis.  With more than 98% reduction in tumor metastasis over a six-week period, in the mouse model, the company is optimistic about the potential for human development. The temporal equivalency of the murine 6 weeks study, may be up to 6 years in humans. 

“These positive pre-clinical results are very promising, and it gives new hope for future treatment options to cancer victims all over the world.  We are working diligently to present an abstract of this data in conference as soon as possible,” said Dr. Nader Pourhassan, President and CEO of CytoDyn.  “Should CytoDyn’s mouse xenograft breast cancer metastasis studies using leronlimab (PRO 140) correlate in humans (as Pfizer’s drug maraviroc did in colon cancer, in a trial conducted in Germany (see results on CytoDyn’s website (www.cytodyn.com)), this could open new possibilities for treatment options for breast cancer.  New treatment options of this kind would be welcome news for late stage cancer patients, who often experience deadly metastasis.”

Dr. Pourhassan continued, “We look forward with great anticipation to receiving interim data from our human trial in triple-negative breast cancer (TNBC), which is expected to be available within the next few months. If interim results are positive, we will promptly file for breakthrough therapy designation.” Dr. Pourhassan continued, “Negotiation of potential licensing opportunities has started on several fronts.  We hope to reach a definitive deal regarding a commercialization partnership for HIV and/or GvHD, which would further enhance the trajectory of our company.”

If you found this helpful feel free to email me.


Edited by FullTilt - Mar 03 2019 at 3:08pm
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 13161
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Mar 04 2019 at 10:51pm
An early Phase 1 study of only 48 trial participants?  Is Chicago the only study location?
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
FullTilt View Drop Down
Newbie
Newbie


Joined: Mar 03 2019
Status: Offline
Points: 3
Post Options Post Options   Thanks (0) Thanks(0)   Quote FullTilt Quote  Post ReplyReply Direct Link To This Post Posted: Mar 05 2019 at 9:13am
I believe there are 5 sites. Call the company CytoDyn.
Back to Top
MikeW View Drop Down
Senior Member
Senior Member


Joined: Feb 28 2015
Location: Wash State
Status: Offline
Points: 119
Post Options Post Options   Thanks (0) Thanks(0)   Quote MikeW Quote  Post ReplyReply Direct Link To This Post Posted: Mar 07 2019 at 11:40am
This is all great news especially since we live in Vancouver, WA. Long story cut short: My wife's ER/PR+ turned triple negative with extensive and too numerous to count metastasis to spine and hip. Xeloda failed her after 14 months. Next she went on Halaven (eribulen) which wiped out all the cancer after only 3 cycles. She went on for the full 8 cycles. Two PET scans show her clear, she's not been on any chemo now and gets a PET scan in mid-April.
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.